Perrigo Company today announced that its partner Cobrek Pharmaceuticals, Inc. has filed an ANDA for Clindamycin Phosphate Foam 1%, a generic version of Evoclin Foam 1%. The Company believes that Cobrek is the first to file an ANDA with a Paragraph IV certification against Evoclin.
The details can be read here.
No comments:
Post a Comment